Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

143.34 -1.13 (-0.78%)
Streaming Delayed Price Updated: 12:27 PM EST, Jan 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
JNJ Stock Earnings: Johnson & Johnson Beats EPS, Misses Revenue for Q1 2024
JNJ stock results show that Johnson & Johnson beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Q1 Earnings Tops Wall Street Estimates On Strong Medical Devices Sales, Boosts Annual Outlook
Johnson & Johnson reports Q1 results: adjusted EPS $2.71 (up 12.4% Y/Y), sales $21.38B (up 2.3% Y/Y). Explore pharma giant's robust performance, including strong growth in Innovative Medicine and... 
Via Benzinga
Johnson & Johnson is as Cheap as it’s Going to Get
Johnson & Johnson raised its dividend for the 62nd consecutive year and has the power to continue raising the annual payout indefinitely. 
Via MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Macatawa Bank Corporation (Nasdaq - MCBC), Shockwave Medical, Inc. (Nasdaq – SWAV), Apartment Income REIT Corp. (NYSE - AIRC), Model N, Inc. (NYSE – MODN)
From Brodsky & Smith LLC
Via GlobeNewswire
Bellwether Health Giant J&J Beats Earnings Calls, But Shares Dip On Light Sales
The company reported light first-quarter sales, though earnings came in narrowly ahead. 
Via Investor's Business Daily
Earnings Turnaround For Johnson & Johnson With Q1 2024 Financial Results
Pharmaceutical and consumer staples titan Johnson & Johnson reported its Q1 2024 financial results this morning. 
Via Talk Markets
Buyback Bonanza: The Top 7 ETFs to Profit From Corporate Cash Splurges
Profit from corporate cash splurges with these top ETFs targeting buyback strategies. Unlock potential gains in a volatile market. 
Via InvestorPlace
Topics ETFs
Wall Street Braces For Mixed Open As Middle-East Tensions Offset Earnings Optimism: Analyst Points To Silver Lining In Rally Break
Earnings optimism may partly offset worries concerning rising bond yields and the volatile geopolitical situation in the Middle East, with the index futures trading mixed early 
Via Benzinga
Topics Bonds
Exposures Debt Markets
A Closer Look at 9 Analyst Recommendations For Johnson & Johnson
Via Benzinga
Earnings Scheduled For April 16, 2024
Companies Reporting Before The Bell • Traws Pharma (NASDAQ:TRAW) is expected to report earnings for its fourth quarter. 
Via Benzinga
Star Surgical Shines as U.S. Outlook Improves for 2024
STAAR Surgical is increasing its outlook and guidance as demand for its signature IOL procedure increases with an aging population 
Via MarketBeat
Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%
From Johnson & Johnson
Via Business Wire
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
Healthcare stocks disappointed again last week with the XLV down over 3% and up only 1.65 % YTD, in a continued downtrend since March 28. 
Via Talk Markets
Johnson & Johnson Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Johnson & Johnson (NYSE: JNJ) is set to release earnings results for its first quarter before the opening bell on April 16, 2024. 
Via Benzinga
Bank of America, Morgan Stanley And 3 Stocks To Watch Heading Into Tuesday
With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Fear & Greed Index Moves To 'Fear' Zone; S&P 500 Down Over 1%
The CNN Money Fear and Greed index showed a decline in the overall market sentiment, with the index moving to the "Fear" zone on Monday. U.S. stocks closed lower on Friday amid concerns over the... 
Via Benzinga
Topics Stocks
Exposures US Equities
J&J Braces For Q1 Earnings With Bearish Charts And Patent Cliffs In Play
Johnson & Johnson's Q1 earnings report on April 16 is expected to show $2.64 EPS and $21.4 billion in revenues. Technical analysis shows a bearish trend but analysts have a neutral rating with a... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Medical Device Manufacture Integer To Gain From Expanding Pulsed Field Ablation Market, Earns Upgrade From BofA
BofA Securities' upgrades Integer, highlighting the growth potential of pulsed field ablation (PFA) in atrial fibrillation treatment. With projections of PFA sales skyrocketing from $100-200 million in... 
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Shockwave Medical, Inc. (Nasdaq – SWAV), Apartment Income REIT Corp. (NYSE - AIRC), Model N, Inc. (NYSE – MODN), ARCA biopharma, Inc. (Nasdaq - ABIO)
From Brodsky & Smith LLC
Via GlobeNewswire
The 3 Best Stocks to Buy to Survive the Coming S&P 500 Crash
You never know when a downturn will hit so it pays to prepare for the worst by buying these stocks before a market crash. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
MarketBeat Week in Review – 4/8 - 4/12
The latest inflation readings moved stocks lower as investors reconsidered what higher-for-longer interest rates mean for corporate earnings and stock valuation 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
3 Quarterly Releases To Watch Next Week
Earnings season is always an exciting time for investors, with companies finally revealing what’s transpired behind closed doors. 
Via Talk Markets
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
The weekly Benzinga Stock Whisper Index highlights five stocks that saw increased interest from readers. Here are this week's stocks to watch. 
Via Benzinga
5 Dividend Kings That Yield More Than Vanguard's Top Value ETF
Despite a thriving bull market, some Dividend Kings still yield more than the Vanguard Value ETF's 2.4% payout. 
Via The Motley Fool
Topics ETFs
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024. 
Via InvestorPlace
All-Time High Flyers: 7 Stocks to Buy as the Market Peaks
These stocks to buy have enjoyed big rallies and the gains look likely to continue in coming months even if the market does peak. 
Via InvestorPlace
5 Things To Know In Investing This Week - The Shockwave Takeover Issue
The Shockwave offer that DKI predicted in December happened this week with Johnson & Johnson (NYSE: JNJ)agreeing to pay $335 per share in cash. DKI subscribers celebrated! The PMI came in  hot. Don’t... 
Via Benzinga
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease. 
Via InvestorPlace
Rare Disease-Focused Rallybio Inks Development Pact With Johnson & Johnson, Stock Shoots Higher
Rallybio partners with Johnson & Johnson to develop therapies targeting fetal and neonatal alloimmune thrombocytopenia, receiving $6.6 million investment. Phase 2 study for RLYB212 set for 2024. 
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.